Log In
BCIQ
Print this Print this
 

BBT-030

  Manage Alerts
Collapse Summary General Information
Company Bolder BioTechnology Inc.
DescriptionLong-acting interleukin-11 (IL-11)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationThrombocytopenia
Indication DetailsTreat thrombocytopenia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today